血清miR-92b水平对胸段食管癌患者胸腔镜术后复发的预测  

Prediction of Serum miR-92b Levels for Postoperative Recurrence in Patients with Thoracic Esophageal Cancer Undergoing Thoracoscopic Surgery

作　　者：王启昕 朱正帅 杨子林 陈顺 杨富涛[1] 王旸[1] Wang Qixin;Zhu Zhengshuai;Yang Zilin(Department of Thoracic Surgery,Nanyang Central Hospital,Nanyang,Henan,473000,China)

机构地区：[1]南阳市中心医院胸外科,河南南阳473000

出　　处：《黑龙江医学》2025年第6期647-650,共4页Heilongjiang Medical Journal

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ202107978)。

摘　　要：目的:探讨血清微小RNA-92b (miR-92b)对胸段食管癌患者胸腔镜术后复发的预测价值。方法:选取2019年6月—2022年6月南阳市中心医院收治的150例行胸腔镜食管癌根治术治疗的胸段食管癌患者作为研究对象。所有患者术前均接受miR-92b实时荧光定量PCR法检测。术后开展为期12个月的随访,统计随访期间患者癌症复发情况并依据结局将患者分为复发组和未复发组。设计患者基线资料调查表,将可能的因素纳入其中,重点探讨血清miR-92b水平与胸段食管癌患者胸腔镜术后复发的关系。绘制受试者工作特征(ROC)曲线,分析血清miR-92b水平预测胸段食管癌患者胸腔镜术后复发的价值。结果:150例胸段食管癌患者中,胸腔镜术后复发31例,未复发119例。复发组血清miR-92b表达量低于未复发组,差异有统计学意义(t=4.446,P<0.001)。logistic回归分析结果显示,癌组织浸润程度深、TNM分期Ⅲ期是患者胸腔镜术后复发的危险因素(OR=4.609、4.775,P<0.05);术前血清miR-92b过表达是患者胸腔镜术后复发的保护因素(OR=0.001,P<0.05)。ROC曲线结果显示,术前血清miR-92b预测胸段食管癌患者胸腔镜术后复发的AUC为0.742,预测价值中等。结论:胸段食管癌患者胸腔镜术前miR-92b低表达与术后复发有关,术前早期检测患者miR-92b表达,可用于预测术后复发风险。Objective:To explore the predictive value of serum microRNA-92b(miR-92b)for postoperative recurrence in patients with thoracic esophageal cancer undergoing thoracoscopy.Methods:A prospective study was conducted on 150 patients with thoracic esophageal cancer who underwent thoracoscopic esophagectomy in the hospital from June 2019 to June 2022.All patients underwent miR-92b real-time fluorescence quantitative PCR detection before surgery.A follow-up period of 12 months was conducted after surgery,and the cancer recurrence rate of patients during the follow-up period was counted.Patients were divided into recurrence group and non recurrence group based on the outcome.A baseline data questionnaire was designed to include possible factors,focusing on the relationship between serum miR-92b level and postoperative recurrence in patients with thoracic esophageal cancer.Receiver operating characteristic(ROC)curve was drawn to analyze the value of serum miR-92b level in predicting postoperative recurrence in patients with thoracic esophageal cancer.Results:Among 150 patients with thoracic esophageal cancer,31 recurred after thoracoscopic operation,and 119 did not.The expression level of miR-92b in the recurrent group was lower than that in the non-recurrent group,and the difference was statistically significant(t=4.446,P<0.001).Logistic regression analysis showed that the degree of cancer tissue infiltration and TNM stageⅢwere risk factors for patients with thoracoscopic postoperative recurrence(OR=4.609,4.775;P<0.05),and preoperative serum miR-92b overexpression was a protective factor for patients with thoracoscopic postoperative recurrence(OR=0.001,P<0.05).Results of ROC curve show that preoperative serum miR-92b predicted the AUC of thoracoscopic postoperative recurrence in patients with thoracic esophageal cancer was 0.742,indicating moderate predictive value.Conclusion:Low expression of miR-92b before thoracoscopic surgery is associated with postoperative recurrence in patients with thoracic esophageal cancer.Earl

关 键 词：胸段食管癌 胸腔镜食管癌根治术 微小RNA-92b 复发 预测 

分 类 号：R73[医药卫生—肿瘤]